CORT insider ownership: who sold, why, and what they still hold

What stands out

Leonard Baker Jr. bought 100K shares for $3.3M, first on Mar 17, 2026. These are the first by current officers or directors since Jun 11, 2021.Purchase, Mar 17, 2026

Two insiders sold $4.4M with no disclosed plan: Kimberly Park ($3.3M) and Gary Robb ($1.2M). The filings don't state a reason.Kimberly Park: largest such sale, Aug 26, 2026 · Gary Robb: largest such sale, Aug 17, 2026

Selling picked up in the last 90 days: officers and directors sold 455K shares, against an average of 219K per 90 days earlier in the period. Most of it was Sean Maduck (106K shares in the last 90 days) and David Mahoney (104K shares in the last 90 days); 91% of these sales were under disclosed plans.Sean Maduck: largest recent sale, Aug 25, 2026 · David Mahoney: largest recent sale, Aug 18, 2026

A share of stake is shown for 0 of the 10 officers and directors who sold. 17 are left out

Left out: Leonard Baker Jr., Joseph Belanoff, James Wilson, David Mahoney, Hazel Hunt, Sean Maduck, Gary Robb, Atabak Mokari, Justin Gunn, Joseph Lyon, William Guyer, Roberto Vieira, Daniel Swisher Jr., Kimberly Park, Gregg Alton, Gillian Cannon and Joshua Murray (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Sean Maduck

President, Corcept Endocrinology The

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$24.5MDisclosed plan

Atabak Mokari

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$18.7MDisclosed plan

William Guyer

Chief Development Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$13.5M95% planned 5% no plan disclosed

David Mahoney

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$12.3MDisclosed plan

Joseph Belanoff

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$10.4MDisclosed plan

All 10 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Oct 2, 20263 executives sold 42K shares ($4.9M) under a disclosed trading plan. 42K shares came in from vesting or option exercises the same day, so their combined holdings rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Sean Maduck President, Corcept Endocrinology The	24,587	$116.28	n/a	n/a	Oct 2, 2026	Oct 5, 2026
Joseph Lyon Chief Accounting & Technology Officer	9,190	$116.13	n/a	n/a	Oct 2, 2026	Oct 5, 2026
Roberto Vieira President, Oncology	8,333	$116.10	n/a	n/a	Oct 2, 2026	Oct 5, 2026

Oct 1, 20262 executives sold 1.2K shares ($141K) under a disclosed trading plan. 1.2K shares came in from vesting or option exercises the same day, so their combined holdings rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Joseph Lyon Chief Accounting & Technology Officer	810	$115.40	n/a	n/a	Oct 1, 2026	Oct 5, 2026
Sean Maduck President, Corcept Endocrinology The	413	$115.54	n/a	n/a	Oct 1, 2026	Oct 5, 2026

Sep 24, 2026Gary Robb gave away 17K shares as a gift.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Gary Robb Chief Business Officer	17,100	n/a	n/a	n/a	Sep 24, 2026	Sep 28, 2026

Sep 16, 2026Roberto Vieira sold 296 shares ($30K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Roberto Vieira President, Oncology	296	$100.82	n/a	n/a	Sep 16, 2026	Sep 18, 2026

Sep 15, 2026James Wilson sold 10K shares ($1.1M) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
James Wilson Director	10,000	$110.69	n/a	n/a	Sep 15, 2026	Sep 16, 2026

Show all 6 events

Sep 14, 2026Joseph Lyon sold 10K shares ($1.1M) under a disclosed trading plan. 10K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Joseph Lyon Chief Accounting & Technology Officer	10,000	$113.49	n/a	n/a	Sep 14, 2026	Sep 16, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

David Mahoney sold $1.7M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Corcept Therapeutics Inc CEO selling stock?

Yes. Joseph Belanoff sold 159K shares ($10.4M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Corcept Therapeutics Inc insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 94% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 6% had no disclosed plan. A trading plan schedules sales in advance.

Are any Corcept Therapeutics Inc insiders buying?

Yes. 1 officer or director reported 2 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold10 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Sean Maduck President, Corcept Endocrinology The	$24.5M 271K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Atabak Mokari Chief Financial Officer	$18.7M 200K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
William Guyer Chief Development Officer	$13.5M 209K shares	Not confirmed share of stake is being verified. Why	95% under a disclosed plan 5% no plan disclosed
David Mahoney Director	$12.3M 104K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Joseph Belanoff Chief Executive Officer, Director	$10.4M 159K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Roberto Vieira President, Oncology	$7.5M 67K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
James Wilson Director	$3.9M 40K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Joseph Lyon Chief Accounting & Technology Officer	$3.6M 37K shares	Not confirmed share of stake is being verified. Why	86% under a disclosed plan 14% no plan disclosed
Kimberly Park Director	$3.3M 27K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Gary Robb Chief Business Officer	$1.2M 10K shares	Not confirmed share of stake is being verified. Why	No plan disclosed

Sold by a charitable foundation the insider reports: Black Dog Private Foundation, Foundation, reported by David Mahoney (sold $1.7M). A foundation's shares are not the insider's own stake, so they are left out of the figures above.

Board members representing outside shareholders, reported separately: Leonard Baker Jr.. Details

The full ownership picture0 of 17 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Leonard Baker Jr.

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Leonard Baker Jr. are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Leonard Baker Jr.

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Leonard Baker Jr. are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
30,000	$28.09	May 16, 2034	$2.7M
15,000	$72.27	Jun 10, 2035	$665K
12,500	$59.69	May 21, 2036	$711K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Joseph Belanoff

Chief Executive Officer, Director

n/a

−159K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Belanoff

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Belanoff are complete; balances and unit counts will be added when the check is finished.

−243Kgifted (net of own trusts)

−307Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
500,000	$23.01	Feb 9, 2034	$46.8M
350,000	$60.58	Feb 28, 2035	$19.6M
460,000	$35.70	Feb 27, 2036	$37.2M

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

James Wilson

Director

n/a

−40K

n/a

Vesting, gifts, unvested awards and holding lines for James Wilson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Wilson are complete; balances and unit counts will be added when the check is finished.

−1.42Mgifted (net of own trusts)

−11Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
80,000	$28.09	May 16, 2034	$7.1M
25,000	$72.27	Jun 10, 2035	$1.1M
12,500	$59.69	May 21, 2036	$711K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

David Mahoney

Director

n/a

−104K

n/a

Vesting, gifts, unvested awards and holding lines for David Mahoney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Mahoney are complete; balances and unit counts will be added when the check is finished.

−25Kgifted (net of own trusts)

−5.5Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
30,000	$28.09	May 16, 2034	$2.7M
15,000	$72.27	Jun 10, 2035	$665K
12,500	$59.69	May 21, 2036	$711K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Hazel Hunt

Chief Scientific Officer

n/a

Vesting, gifts, unvested awards and holding lines for Hazel Hunt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hazel Hunt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−78Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
200,000	$23.01	Feb 9, 2034	$18.7M
140,000	$60.58	Feb 28, 2035	$7.8M
140,000	$35.70	Feb 27, 2036	$11.3M

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Sean Maduck

President, Corcept Endocrinology The

n/a

−271K

n/a

Vesting, gifts, unvested awards and holding lines for Sean Maduck

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sean Maduck are complete; balances and unit counts will be added when the check is finished.

−55Kgifted (net of own trusts)

−814withheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
41,986	$8.27	Feb 10, 2027	$4.5M
169,045	$11.35	Feb 7, 2029	$17.8M
200,000	$23.01	Feb 9, 2034	$18.7M
140,000	$60.58	Feb 28, 2035	$7.8M
140,000	$35.70	Feb 27, 2036	$11.3M

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Gary Robb

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Gary Robb are complete.

Chief Business Officer

n/a

−10K

n/a

Vesting, gifts, unvested awards and holding lines for Gary Robb

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gary Robb are complete; balances and unit counts will be added when the check is finished.

−17Kgifted (net of own trusts)

−81Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
182,507	$8.27	Feb 10, 2027	$19.8M
200,000	$23.01	Feb 9, 2034	$18.7M
140,000	$60.58	Feb 28, 2035	$7.8M
140,000	$35.70	Feb 27, 2036	$11.3M

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Atabak Mokari

Chief Financial Officer

n/a

−200K

n/a

Vesting, gifts, unvested awards and holding lines for Atabak Mokari

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Atabak Mokari are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−711withheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,167	$19.26	Feb 1, 2032	$406K
95,833	$23.06	Feb 12, 2033	$9.0M
200,000	$23.01	Feb 9, 2034	$18.7M
140,000	$60.58	Feb 28, 2035	$7.8M
140,000	$35.70	Feb 27, 2036	$11.3M

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Justin Gunn

President, Corcept Endocrinology The

n/a

Vesting, gifts, unvested awards and holding lines for Justin Gunn

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Justin Gunn are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,000	$37.94	Aug 1, 2034	$2.0M
25,000	$60.58	Feb 28, 2035	$1.4M
13,438	$35.70	Feb 27, 2036	$1.1M
8,959	$35.70	Feb 27, 2036	$725K
100,000	$114.03	Oct 1, 2036	$256K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Joseph Lyon

Chief Accounting & Technology Officer

n/a

−37K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Lyon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Lyon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−540withheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
44,167	$19.26	Feb 1, 2032	$4.3M
150,000	$23.01	Feb 9, 2034	$14.0M
140,000	$60.58	Feb 28, 2035	$7.8M
140,000	$35.70	Feb 27, 2036	$11.3M

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

William Guyer

Chief Development Officer

n/a

−209K

n/a

Vesting, gifts, unvested awards and holding lines for William Guyer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Guyer are complete; balances and unit counts will be added when the check is finished.

−6.1Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
110,000	$21.65	Aug 31, 2031	$10.4M
30,000	$19.26	Feb 1, 2032	$2.9M
200,000	$23.01	Feb 9, 2034	$18.7M
140,000	$60.58	Feb 28, 2035	$7.8M
140,000	$35.70	Feb 27, 2036	$11.3M

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Roberto Vieira

President, Oncology

n/a

−67K

n/a

Vesting, gifts, unvested awards and holding lines for Roberto Vieira

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Roberto Vieira are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−102withheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
133,334	$21.63	Feb 1, 2034	$12.7M
140,000	$60.58	Feb 28, 2035	$7.8M
140,000	$35.70	Feb 27, 2036	$11.3M

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Daniel Swisher Jr.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Daniel Swisher Jr.

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daniel Swisher Jr. are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,950	$5.86	Jul 21, 2026	$991K
30,000	$28.09	May 16, 2034	$2.7M
1,100	$14.08	Aug 20, 2028	$113K
15,000	$72.27	Jun 10, 2035	$665K
12,500	$59.69	May 21, 2036	$711K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Kimberly Park

Director

n/a

−27K

n/a

Vesting, gifts, unvested awards and holding lines for Kimberly Park

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kimberly Park are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−3.3Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
30,000	$13.49	Sep 17, 2029	$3.1M
30,000	$28.09	May 16, 2034	$2.7M
15,000	$72.27	Jun 10, 2035	$665K
12,500	$59.69	May 21, 2036	$711K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Gregg Alton

Director

n/a

Vesting, gifts, unvested awards and holding lines for Gregg Alton

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gregg Alton are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
30,000	$28.09	May 16, 2034	$2.7M
15,000	$72.27	Jun 10, 2035	$665K
12,500	$59.69	May 21, 2036	$711K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Gillian Cannon

Director

n/a

Vesting, gifts, unvested awards and holding lines for Gillian Cannon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gillian Cannon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
49,000	$22.99	Dec 1, 2030	$4.6M
30,000	$28.09	May 16, 2034	$2.7M
15,000	$72.27	Jun 10, 2035	$665K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Joshua Murray

Director

n/a

Vesting, gifts, unvested awards and holding lines for Joshua Murray

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joshua Murray are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
30,000	$28.09	May 16, 2034	$2.7M
15,000	$72.27	Jun 10, 2035	$665K
12,500	$59.69	May 21, 2036	$711K

Estimate: options held × ($116.58 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Holdings and share of stake for Corcept Therapeutics Inc are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$98.7M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $98.7M across 1,122,783 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $93.0M · 94%

The lighter segment is sales with no plan disclosed in the filing ($5.7M), including tax-related sales outside a plan.

No plan disclosed · $5.7M

Sales with no 10b5-1 plan and no tax reference in the filing. $3.3M of it is Kimberly Park. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Kimberly Park, Aug 26, 2026

Taxes

487,403 shares ($36.8M) were withheld by the company for taxes, which isn't a market sale.

Purchases · 1 buyer (2 trades)

1 officer or director bought shares in this period, in 2 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 67 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Sean Maduck President, Corcept Endocrinology The	271K	$24.5M	100%	25%	Nov 3, 2025 to Oct 2, 2026
Atabak Mokari Chief Financial Officer	200K	$18.7M	100%	19%	Jun 1, 2026 to Jul 30, 2026
William Guyer Chief Development Officer	209K	$13.5M	95%	14%	Nov 5, 2025 to Aug 10, 2026
David Mahoney Director	104K	$12.3M	100%	12%	Aug 18, 2026 to Aug 18, 2026
Joseph Belanoff Chief Executive Officer, Director	159K	$10.4M	100%	11%	Nov 3, 2025 to Jun 1, 2026
Roberto Vieira President, Oncology	67K	$7.5M	100%	8%	Sep 2, 2026 to Oct 2, 2026
James Wilson Director	40K	$3.9M	100%	4%	Jun 16, 2026 to Sep 15, 2026
Joseph Lyon Chief Accounting & Technology Officer	37K	$3.6M	86%	4%	Nov 3, 2025 to Oct 2, 2026
Kimberly Park Director	27K	$3.3M	0%	3%	Aug 26, 2026 to Aug 26, 2026
Gary Robb Chief Business Officer	10K	$1.2M	0%	1%	Aug 17, 2026 to Aug 17, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$7.1M	$6.3M	$0	$728K
Dec 2025	$6.8M	$6.8M	$0	$0
Jan 2026	$704K	$704K	$0	$0
Feb 2026	$817K	$817K	$0	$0
Mar 2026	$2.0M	$2.0M	$0	$0
Apr 2026	$819K	$819K	$0	$0
May 2026	$8.3M	$8.0M	$0	$325K
Jun 2026	$10.9M	$10.9M	$0	$0
Jul 2026	$17.6M	$17.6M	$0	$0
Aug 2026	$27.0M	$22.4M	$0	$4.6M
Sep 2026	$11.6M	$11.6M	$0	$0
Oct 2026	$5.0M	$5.0M	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 13, 2025	Sold	Held Oct 13, 2026	Still held
Leonard Baker Jr. ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Leonard Baker Jr. are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Leonard Baker Jr. Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Leonard Baker Jr. are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 2.1x the 5-year average. 10 insiders sold; the average is 5 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	1.12M	10	$98.7M
Oct 13, 2025 1 year earlier	1.04M	7	$83.8M
Oct 13, 2024 2 years earlier	374K	5	$11.0M
Oct 14, 2023 3 years earlier	222K	6	$6.2M
Oct 14, 2022 4 years earlier	568K	4	$14.7M
Oct 14, 2021 5 years earlier	450K	4	$11.1M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty17 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Corcept Therapeutics Inc are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,192 filings on record, 103 filed in the 12-month period, and how we read them

All 1,192 Forms 3, 4 and 5 on record for Corcept Therapeutics Inc (SEC CIK 1088856), filed from Apr 14, 2004 to Oct 5, 2026; 103 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (36)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Andreas Grauer	Feb 8, 2021	No balance on record
Daniel Bradbury	Feb 12, 2019	130,575 shares, last reported balance as of Feb 7, 2019
Robert Fishman	Nov 9, 2018	No balance on record
Renee Gala	Aug 22, 2018	10,000 shares, last reported balance as of Mar 7, 2018
Patrick Enright	Mar 20, 2017	386,956 shares, last reported balance as of Mar 16, 2017
Patrick Enright	Mar 20, 2017	19,154,945 shares, last reported balance as of Mar 16, 2017
Longitude Venture Partners L.P.	Dec 19, 2016	11,089,541 shares, last reported balance as of Dec 15, 2016
Steven Lo	Nov 16, 2015	585,416 shares, last reported balance as of Nov 16, 2015
Anne LeDoux	Sep 29, 2015	50,000 shares, last reported balance as of Sep 28, 2015
Joseph Turner	Jun 23, 2015	10,000 shares, last reported balance as of Mar 14, 2013
Joseph Cook Jr.	Jun 22, 2015	5,509,237 shares, last reported balance as of Mar 25, 2015
Joseph Cook Jr.	Jun 22, 2015	356,568 shares, last reported balance as of Mar 19, 2015
Stefan Dyckerhoff	Jul 10, 2013	5,420,353 shares, last reported balance as of Nov 1, 2012
Samuel Pullara III	Jul 10, 2013	5,420,353 shares, last reported balance as of Nov 1, 2012
David Anderson	Feb 13, 2013	6,420,729 shares, last reported balance as of Dec 31, 2012
Tench Coxe	Feb 13, 2013	6,890,503 shares, last reported balance as of Nov 12, 2012
James Gaither	Feb 13, 2013	5,545,261 shares, last reported balance as of Mar 29, 2012
William Younger Jr.	Feb 13, 2013	6,353,501 shares, last reported balance as of Aug 14, 2012
Robert Roe	Feb 1, 2013	No balance on record
David Sweet	Apr 2, 2012	4,508,117 shares, last reported balance as of Mar 29, 2012
Andrew Sheehan	Apr 2, 2012	4,482,207 shares, last reported balance as of Mar 29, 2012
Michael Speiser	Apr 2, 2012	4,455,527 shares, last reported balance as of Mar 29, 2012
Gregory Sands	Oct 25, 2011	4,635,284 shares, last reported balance as of Oct 21, 2011
James Harper	Jul 12, 2010	67,400 shares, last reported balance as of Jun 23, 2010
Edward Penhoet	Apr 6, 2010	41,250 shares, last reported balance as of Apr 5, 2010
Edward Penhoet	Apr 6, 2010	5,832,065 shares, last reported balance as of Apr 5, 2010
Alix Marduel	Oct 20, 2009	11,513,196 shares, last reported balance as of Oct 16, 2009
Alix Marduel	Oct 20, 2009	5,209,790 shares, last reported balance as of Mar 25, 2008
Allen Andersson	Jun 29, 2009	2,156,255 shares, last reported balance as of May 7, 2009
Paperboy Ventures, LLC	May 11, 2009	209,694 shares, last reported balance as of May 7, 2009
Caroline Loewy	Dec 2, 2008	No balance on record
David Singer	Feb 13, 2008	862,167 shares, last reported balance as of Dec 19, 2007
Alan Schatzberg	Apr 3, 2007	5,127,498 shares, last reported balance as of Mar 30, 2007
Fred Kurland	Mar 6, 2006	7,500 shares, last reported balance as of Dec 20, 2005
Ronald Bernal	Feb 1, 2005	2,298,834 shares, last reported balance as of Feb 1, 2005
Steven Kapp	Apr 14, 2004	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Corcept Therapeutics Inc insiders sold $98.7M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Corcept Therapeutics Inc CEO selling stock?

Why are Corcept Therapeutics Inc insiders selling?

Are any Corcept Therapeutics Inc insiders buying?

The evidence

No plan disclosed · $5.7M

Taxes

Purchases · 1 buyer (2 trades)

Sales by month